DP
FHTX icon

Diadema Partners’s Foghorn Therapeutics FHTX Stock Holding History

Diadema Partners’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$382K Buy
79,944
+49,314
+161% +$271K 0.07% 117
2025
Q4 		$165K Sell
30,630
-19,370
-39% -$87.8K 0.03% 132
2025
Q3 		$245K Buy
+50,000
New +$265K 0.06% 112

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Diadema Partners's FHTX Position: Q1 2026 in Review

Diadema Partners increased its Foghorn Therapeutics (FHTX) stake by 161% in Q1 2026, buying an estimated $271K and bringing the position to 79,944 shares worth $382K. The position accounts for 0.07% of the portfolio, ranked #117.

Diadema Partners first reported a position in FHTX in Q3 2025 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Diadema Partners held 79,944 shares of Foghorn Therapeutics worth $382K as of Q1 2026.
  • Diadema Partners bought 49,314 Foghorn Therapeutics shares in Q1 2026, an estimated $271K.
  • Foghorn Therapeutics made up 0.07% of Diadema Partners's portfolio in Q1 2026, its #117 holding.
  • Diadema Partners first reported a position in Foghorn Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.